Literature DB >> 11343249

Etiologic significance of defects in cholesterol, phospholipid, and bile acid metabolism in the liver of patients with intrahepatic calculi.

J Shoda1, K Oda, H Suzuki, Y Sugiyama, K Ito, D E Cohen, L Feng, J Kamiya, Y Nimura, H Miyazaki, M Kano, Y Matsuzaki, N Tanaka.   

Abstract

Intrahepatic calculi, highly prevalent in the Far East, including Japan, are characterized clinically by chronic proliferative cholangitis with frequent stone recurrences. Intrahepatic calculi consist of 2 groups, i.e., brown pigment stones, including a high cholesterol content, and cholesterol stones, with the former predominating. To gain insights into the pathogenesis of intrahepatic calculi, cholesterol and bile acid biosynthesis, as well as alterations in intracellular transport and/or canalicular secretion of phospholipid and bile acid were investigated in liver of patients with intrahepatic calculi. Enzyme activities of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase were increased (12.8 +/- 1.9 pmol/min/mg protein, mean +/- SEM vs. 5.5 +/- 0.4 in controls; P < .01) and cholesterol 7 alpha-hydroxylase activities were decreased (1.3 +/- 0.4 vs. 4.9 +/- 0.6; P < .01) in liver specimens of patients with brown pigment stones. In addition, messenger RNA (mRNA) levels of multidrug resistance P-glycoprotein 3 (MDR3 Pgp) and phosphatidylcholine transfer protein (PCTP) were markedly low in the liver specimens compared with the levels in specimens of control subjects, gallbladder stone patients, and patients with obstructive cholestasis. The protein levels and the immunohistochemical staining were decreased for MDR3 Pgp and PCTP in the liver. Consistently, the concentrations of phospholipid were markedly reduced in the hepatic bile from both affected and unaffected hepatic segments. In patients with intrahepatic calculi, biliary cholesterol supersaturation and the formation of cholesterol-rich brown pigment as well as cholesterol stones may be attributed to decreased hepatic transport and biliary secretion of phospholipids, in the setting of increased cholesterogenesis and decreased bile acid synthesis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11343249     DOI: 10.1053/jhep.2001.23936

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  16 in total

1.  A polymorphism in New Zealand inbred mouse strains that inactivates phosphatidylcholine transfer protein.

Authors:  Huei-Ju Pan; Diana S Agate; Benjamin L King; Michele K Wu; Steven L Roderick; Edward H Leiter; David E Cohen
Journal:  FEBS Lett       Date:  2006-10-06       Impact factor: 4.124

2.  Genetic ablation or chemical inhibition of phosphatidylcholine transfer protein attenuates diet-induced hepatic glucose production.

Authors:  Ekaterina Y Shishova; Janis M Stoll; Baran A Ersoy; Sudeep Shrestha; Erez F Scapa; Yingxia Li; Michele W Niepel; Ya Su; Linda A Jelicks; Gregory L Stahl; Marcie A Glicksman; Roger Gutierrez-Juarez; Gregory D Cuny; David E Cohen
Journal:  Hepatology       Date:  2011-06-23       Impact factor: 17.425

3.  Aspects of liver pathology in adult patients with MDR3/ABCB4 gene mutations.

Authors:  Dominique Wendum; Véronique Barbu; Olivier Rosmorduc; Lionel Arrivé; Jean-François Fléjou; Raoul Poupon
Journal:  Virchows Arch       Date:  2012-02-14       Impact factor: 4.064

Review 4.  Genetic analysis of cholesterol gallstone formation: searching for Lith (gallstone) genes.

Authors:  David Q-H Wang; Nezam H Afdhal
Journal:  Curr Gastroenterol Rep       Date:  2004-04

Review 5.  Structure and function of phosphatidylcholine transfer protein (PC-TP)/StarD2.

Authors:  Keishi Kanno; Michele K Wu; Erez F Scapa; Steven L Roderick; David E Cohen
Journal:  Biochim Biophys Acta       Date:  2007-04-12

6.  Small-molecule inhibitors of phosphatidylcholine transfer protein/StarD2 identified by high-throughput screening.

Authors:  Neil Wagle; Jun Xian; Ekaterina Y Shishova; Jie Wei; Marcie A Glicksman; Gregory D Cuny; Ross L Stein; David E Cohen
Journal:  Anal Biochem       Date:  2008-08-12       Impact factor: 3.365

Review 7.  Hepatolithiasis and intrahepatic cholangiocarcinoma: A review.

Authors:  Hyo Jung Kim; Jae Seon Kim; Moon Kyung Joo; Beom Jae Lee; Ji Hoon Kim; Jong Eun Yeon; Jong-Jae Park; Kwan Soo Byun; Young-Tae Bak
Journal:  World J Gastroenterol       Date:  2015-12-28       Impact factor: 5.742

8.  Common variants of ABCB4 and ABCB11 and plasma lipid levels: a study in sib pairs with gallstones, and controls.

Authors:  Monica Acalovschi; Simona Tirziu; Erica Chiorean; Marcin Krawczyk; Frank Grünhage; Frank Lammert
Journal:  Lipids       Date:  2009-04-30       Impact factor: 1.880

9.  Expression of deleted in malignant brain tumor-1 (DMBT1) molecule in biliary epithelium is augmented in hepatolithiasis: possible participation in lithogenesis.

Authors:  Motoko Sasaki; Shiu-Feng Huang; Miin-Fu Chen; Yi-Yin Jan; Ta-Sen Yeh; Akira Ishikawa; Jan Mollenhauer; Annemarie Poustka; Koichi Tsuneyama; Yuji Nimura; Koji Oda; Yasuni Nakanuma
Journal:  Dig Dis Sci       Date:  2003-07       Impact factor: 3.199

Review 10.  Biliary lipids and cholesterol gallstone disease.

Authors:  David Q-H Wang; David E Cohen; Martin C Carey
Journal:  J Lipid Res       Date:  2008-11-17       Impact factor: 5.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.